The term “molecular partners” carries a fascinating duality in 2026’s biopharmaceutical landscape. In the laboratory, it describes the fundamental biological reality of how proteins, nucleic acids, and small molecules interact through specific binding relationships to drive cellular functions. These binding partnerships, from antibody-antigen complexes to enzyme-substrate interactions, form the mechanistic foundation of modern therapeutic development. Yet when industry professionals search for this term, they’re increasingly seeking something different: strategic collaborations between biotech firms, academic …